SAN CARLOS, Calif.--Nov 10, 2025--CuraSen Therapeutics, Inc., a biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced encouraging results from a Phase 1 study...
Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases
News | 09. 02. 2025
Enlaza Therapeutics
LA JOLLA, Calif., September 2, 2025 – Enlaza Therapeutics, the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals (Nasdaq: VRTX) to utilize Enlaza’s proprietary War-Lock™ technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.
